Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials - Mazza, G L; Mead-Harvey, C; Mascarenhas, J; Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 trial teams (Lancet Haematol, 2022)